What changed for Motor Neurone Disease
A plain English summary of what recently moved in the public data Voxsanity tracks for Motor Neurone Disease. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials on record 881 to 875 (-6)
Newly subsidised on the PBS
No PBS-reviewed medicines are tracked for Motor Neurone Disease yet, so new PBS listings cannot be reported for it. This is a gap in what Voxsanity has mapped, not a statement that no medicines are subsidised — check the PBS directly.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 50 trials tracked for Motor Neurone Disease that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT04220021 · results posted 2 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04220021) enrolled 41 people with a specific genetic form of ALS (a motor neurone disease) caused by a change in a gene called C9orf72, who were already taking the medication metformin. The trial was looking at two main things: whether any unexpected side effects arose during the study period, and whether levels of a particular protein in the fluid around the brain and spine (called a RAN protein, specifically a type known as polyglycine-proline or "GP") changed over time. A total of 23 participants completed the study, wh...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04866771 · results posted 7 August 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04866771) involved 14 people with ALS (a serious neurological condition) who were split into two groups of 7. One group received a brain stimulation technique called transcranial direct current stimulation (tDCS) — which uses a mild electrical current applied to the scalp — while the other group was a delayed-start control group, meaning they were scheduled to receive the same treatment later. The trial was primarily measuring how participants' day-to-day functioning changed over time using a standard ALS questionnaire, an...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05349721 · results posted 1 August 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05349721) looked at a drug called utreloxastat in people living with ALS (also known as motor neurone disease). The trial had three parts. In the first 24-week part, 222 people were assigned to utreloxastat and 114 to a placebo (a dummy treatment with no active ingredient). The main thing researchers were measuring was a combined score that took into account both survival and day-to-day functioning — using a standard ALS questionnaire called the ALSFRS-R, which rates 12 everyday activities on a scale where higher scores me...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT03705390 · results posted 26 June 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03705390) involved a single group of participants who received a treatment called ILB®. Eleven people started the initial 10-week treatment period, and nine completed it (two did not finish). Those nine then moved into an extended treatment phase, with eight completing that stage. The trial's primary focus was on tracking and recording adverse events — that is, any unwanted or unexpected health occurrences that happened during the study — and serious adverse events (SAEs), which are a more severe category involving hospita...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05053035 · results posted 18 June 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05053035) was a small study involving just 5 participants in total — 3 received the investigational treatment AL001 and 2 received a placebo (an inactive substitute). The trial was measuring several things: whether participants experienced any unwanted health events (called adverse events), whether the body produced any immune responses to AL001 (known as antibodies against the drug), how much of the drug appeared in the blood and in cerebrospinal fluid (the fluid surrounding the brain and spine) at 24 weeks, and how level...
-
NCT03645031 · results posted 15 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03645031) looked at whether a breathing treatment called "acute intermittent hypoxia" (AIH) — which involves briefly breathing air with lower oxygen levels than normal — had any measurable effect on breathing muscle strength and hand grip strength in people with ALS (also known as motor neurone disease) compared to healthy volunteers. A total of 29 people started the study across four groups: people with ALS and healthy controls, each receiving either the real AIH treatment first or a sham (fake) version first, then swappi...
-
NCT04579666 · results posted 24 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04579666) looked at a drug called pegcetacoplan in people with ALS (also known as motor neurone disease). The first part of the trial (called the Randomised Treatment Period, or RTP) ran for up to 52 weeks and included 169 people who received pegcetacoplan and 80 people who received a placebo (a dummy treatment with no active ingredient). A second open-label period then ran from week 52 to week 104, where 97 and 50 participants respectively continued on or switched to pegcetacoplan. The trial measured a combined score that...
-
NCT03580616 · results posted 20 April 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 43 people, all of whom received L-Serine, a naturally occurring amino acid. The trial was looking at how well participants tolerated the supplement (based on self-reported stomach and digestive symptoms) and also tracked two other measures: a standard ALS function score (called the ALSFRS-R, which rates a person's ability to carry out 12 everyday activities on a scale from 0 to 48, where higher means better function), and a breathing test called Forced Vital Capacity. It is worth noting that while 43 people started th...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05178810 · results posted 18 March 2025
According to the results reported on ClinicalTrials.gov, this trial looked at a drug called FAB122 compared to a placebo (an inactive treatment) in people living with ALS (Amyotrophic Lateral Sclerosis, also known as Motor Neurone Disease). A total of 205 people were assigned to receive FAB122 and 97 received the placebo. The trial ran for up to 72 weeks and used a standard ALS questionnaire called the ALSFRS-R — a 48-point scale where higher scores mean better day-to-day functioning — as its main way of measuring change over time. The reported data shows that after 48 weeks, participants in...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04607044 · results posted 9 January 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 45 participants, all of whom had a nerve-related condition (neuropathy) and received one or more lower-limb surgical implant devices made by Wright Medical. The trial was measuring things like how many participants kept their limb (i.e., did not need an amputation) over time, as well as how participants felt about their own health, daily activities, and physical function. The reported data shows that none of the 45 participants were recorded as having completed the study — all 45 are listed under "not completed," whic...
-
NCT04944784 · results posted 5 December 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04944784) looked at a drug called reldesemtiv in people living with ALS (amyotrophic lateral sclerosis, also known as motor neurone disease). During the main double-blind period — where neither participants nor researchers knew who was receiving the drug or a dummy treatment (placebo) — 325 people were assigned to reldesemtiv and 161 to placebo. Of those, 180 and 96 respectively completed that phase. The trial's main goal was to measure changes in everyday physical functioning over 24 weeks using a standard ALS rating scal...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05442775 · results posted 13 August 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT05442775) enrolled 71 people who received a treatment called reldesemtiv. The trial was an open-label, long-term study looking at what happened to participants over time when taking this medicine. Notably, the reported data shows that none of the 71 participants were recorded as having formally "completed" the study — all 71 were listed under "not completed," though no further explanation for this is provided in the submitted data. The primary thing the trial was measuring was safety and tolerability over the long term —...
-
NCT04098406 · results posted 3 July 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04098406) looked at a drug called CNM-Au8 (a suspension of gold nanocrystals) in people with ALS (also known as motor neurone disease). A total of 45 people took part — 22 were assigned to a placebo (an inactive treatment) and 23 received a 30 mg daily dose of CNM-Au8. The trial ran for 36 weeks and was primarily measuring changes in nerve and muscle function over time using a specialised electrical test called MUNIX, which gives a score reflecting how many working nerve cells are still supplying certain muscles. A higher...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04490148 · results posted 18 June 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04490148) enrolled 29 people in total — 12 in a remote lung function testing-only group and 17 in a remote lung function testing plus nurse coaching group. The study was looking at whether testing lung function from home (rather than attending a clinic) could pick up earlier when someone might need breathing support (a machine called non-invasive ventilation, or NIV). It also tracked participants' confidence in managing their own health — including their medications, social life, and symptoms — over 12 months, as well as h...
-
NCT04254913 · results posted 24 January 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04254913) enrolled 6 participants, all of whom received the study treatment MT-1186, a form of edaravone. Five participants completed the trial and one did not. The trial was measuring how the drug moves through the body after it is taken — specifically, how quickly it is absorbed into the bloodstream, how high the concentration in the blood gets, and how long it takes for the body to clear it. This type of measurement is known as pharmacokinetics, which simply means tracking how a drug travels through the body over time....
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04470050 · results posted 26 October 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 225 people in total across seven groups. All participants were first stabilised on morphine (a strong painkiller used here to represent opioid dependence) during an initial maintenance phase. They were then moved into a double-blind treatment phase — meaning neither the participants nor the researchers knew who was receiving which treatment — where different groups received one of six doses of an investigational treatment (30, 60, 90, 120, 180, or 240 micrograms) or a placebo (a dummy treatment with no active ingredie...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05039268 · results posted 11 October 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 16 people in total, split into two groups of 8 — one group received a 15mg dose and the other received a 30mg dose of an investigational treatment called 3K3A-APC, which was being studied in the context of ALS (also known as motor neurone disease). All 16 participants completed the study. The trial was primarily measuring two things: whether participants experienced any serious unwanted health events (called adverse events) during the study, and whether there were any changes in a brain scan measure called the PERSI s...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT04615923 · results posted 23 August 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04615923) looked at a medicine called pridopidine in people living with ALS (also known as motor neurone disease). A total of 162 people took part — 120 received pridopidine and 42 received a matching placebo (a dummy treatment with no active ingredient). Of those, 96 people in the pridopidine group and 38 in the placebo group completed the study. The trial was mainly measuring two things: how quickly participants' physical function declined over time (using a standardised ALS rating scale scored out of 48, where higher sc...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02623699 · results posted 28 July 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT02623699) tested a drug called BIIB067 (also known as tofersen) and was conducted in three parts. Parts A and B were early-phase dosing studies involving healthy or at-risk volunteers who received either BIIB067 at various doses (10 mg, 20 mg, 40 mg, 60 mg, or 100 mg) or a placebo (an inactive substance used for comparison). Part C was a larger pivotal stage involving 108 participants — 72 received BIIB067 at 100 mg and 36 received placebo. In total, across all three parts, around 178 people took part. The main things bein...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04414345 · results posted 25 July 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04414345) looked at a treatment called CNM-Au8 in people living with ALS (also known as motor neurone disease). A total of 161 people took part — 120 received CNM-Au8 and 41 received a matching placebo (a dummy treatment with no active ingredient). The trial was measuring two main things: how quickly participants' physical function declined over time (using a standard ALS rating scale called the ALSFRS-R, where higher scores mean better physical ability out of a maximum of 48), and the rate of death or the need for round-t...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04322149 · results posted 28 June 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04322149) tested a treatment called AT-1501 across four different dose levels: 1.0 mg/kg, 2.0 mg/kg, 4.0 mg/kg, and 8.0 mg/kg. A total of 54 people took part — 9 in each of the two lower-dose groups and 18 in each of the two higher-dose groups. Most participants completed the study, with 49 out of 54 finishing. The trial's main focus was on tracking adverse events — that is, any unwanted or unexpected health changes that occurred while participants were receiving the treatment (called Treatment Emergent Adverse Events, or...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05003167 · results posted 8 June 2023
According to the results reported on ClinicalTrials.gov, this trial involved 13 participants who all received a treatment called Expiratory Muscle Strength Training (EMST) — a type of breathing exercise where a person blows forcefully into a special device to build up the muscles used when breathing out. Twelve of the 13 participants completed the study. The trial was measuring whether this training changed how strongly participants could breathe out, how forcefully they could cough, and certain aspects of their speech — such as how many words they could say in one breath and where they paused...
-
NCT03456882 · results posted 21 April 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03456882) enrolled 147 people with ALS (motor neurone disease) — 74 received an investigational treatment called RNS60 and 73 received normal saline (a saltwater solution used as a comparison). All participants were also taking riluzole, a standard ALS medication. The trial set out to measure how RNS60 affected certain biological markers in the blood — substances that researchers use to track what is happening inside the body at a cellular level. Of those who started, 60 in the RNS60 group and 50 in the saline group comple...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03948178 · results posted 9 March 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03948178) enrolled 227 people, all of whom received a medicine called levosimendan. The trial was measuring a number of things related to safety and body function over time, including adverse events (unwanted health events that occurred during the study), heart rate, heart electrical activity (via ECG recordings), lung breathing capacity, a standard ALS function score, and whether participants withdrew from the study due to their disease getting worse. The reported data shows that none of the 227 participants were recorded...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04248465 · results posted 10 January 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04248465) looked at a medicine called ravulizumab as a potential treatment for ALS (also known as motor neurone disease), a condition that progressively affects the nerves controlling movement and breathing. A total of 382 people took part — 255 received ravulizumab from the start, and 127 received a dummy treatment (placebo) before later switching to ravulizumab in an open-label extension phase. The main thing the trial was measuring was how participants' ability to carry out everyday functions changed over time, using a...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03411863 · results posted 25 October 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03411863) enrolled two groups of participants: 8 people without any neurological disease and 11 people with Amyotrophic Lateral Sclerosis (ALS, also known as motor neurone disease). Of those who started, 5 people in the non-neurological group and 9 people in the ALS group completed the study. The trial was measuring electrical activity in a hand muscle (the muscle at the base of the thumb) in response to a brain stimulation technique, both at rest and during movement. The researchers were looking at whether adding electric...
-
NCT01622088 · results posted 7 April 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 616 people who all received dexpramipexole at a dose of 300 mg per day (taken as 150 mg twice daily). The trial was set up as a long-term monitoring study, meaning its primary focus was on tracking and recording any unwanted health events — sometimes called adverse events — that participants experienced while taking the study drug, rather than measuring whether the drug treated a particular condition. None of the 616 participants were recorded as having completed the study in the standard sense, as the study design me...
-
NCT04947436 · results posted 4 November 2021
According to the results reported on ClinicalTrials.gov, this trial looked at three different airway clearance approaches for people with breathing difficulties: a vest-like device that vibrates the chest wall (High Frequency Chest Wall Oscillation), a machine that helps push air in and pull it out of the lungs (Mechanical Insufflation/Exsufflation), or a combination of both. A total of 28 people started the trial — 7 in the chest wall oscillation group, 10 in the insufflation/exsufflation group, and 11 in the combination group. The trial measured changes in respiratory (breathing-related) com...
-
NCT00326625 · results posted 20 October 2021
According to the results reported on ClinicalTrials.gov, this trial looked at a drug called glatiramer acetate (at a 40mg dose) compared to a placebo (an inactive treatment) in people with ALS (also known as motor neurone disease). A total of 184 people were assigned to the glatiramer acetate group and 182 to the placebo group. The main thing the trial was measuring was how quickly participants' ability to carry out daily activities declined over time, using a standardised questionnaire called the ALSFRS-R, where a higher score means less disability. The trial also tracked how long it took bef...
-
NCT03505021 · results posted 31 August 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03505021) enrolled 496 people with ALS (also known as motor neurone disease) — 329 received levosimendan and 167 received a placebo (a dummy treatment with no active ingredient). Of those who started, 217 in the levosimendan group and 112 in the placebo group completed the study. The trial was primarily measuring whether levosimendan made a difference to breathing capacity (specifically a lung test called "slow vital capacity," measured lying down) over 12 weeks, compared to placebo. Several secondary measures were also tr...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 50 reported results for Motor Neurone Disease
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, Motor Neurone Disease attracts a very large amount of public research funding from the United States, and that level of investment has remained broadly steady year on year. For patients, this signals that MND is taken seriously as a research priority by one of the world's largest public funders of medical science. A sustained and substantial funding base like this ge...
See the full Motor Neurone Disease page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.